Company Overview and News


Add AZN
to your dashboard

Headline News

Parkinson's Space in Focus as Acorda Stops Tozadenant Trial

2017-11-22 zacks
Acorda Therapeutics, Inc. (ACOR - Free Report) recently announced that it is scrapping development of one of its lead Parkinson’s disease (“PD”) candidates, tozadenant. The decision was taken after some serious safety issues were observed in the phase III study, which was reported last week. (137-0)

Acorda Stock Up Despite Phase III Trial on Tozadenant Stops

2017-11-21 zacks
Acorda Therapeutics, Inc. (ACOR - Free Report) announced that it has decided to immediately discontinue the phase III study on one of its lead Parkinson’s disease (“PD”) candidates, tozadenant. (99-0)

TESARO (TSRO) Ovarian Cancer Drug Zejula Gets Approval in EU

2017-11-21 zacks
TESARO, Inc. (TSRO - Free Report) announced that the European Commission has granted marketing authorization to its PARP inhibitor, Zejula, as monotherapy for the maintenance treatment of women with recurrent ovarian cancer. The drug is the first approved PARP inhibitor in Europe, which does not require BRCA mutation or other biomarker testing. (83-1)

Can Valeant (VRX) Turn Around on Rebuilding Initiatives?

2017-11-21 zacks
Shares of Valeant Pharmaceuticals International Inc. (VRX - Free Report) have rallied 7.2% year to date compared with the industry’s gain of 2.4%. (242-2)

The Zacks Analyst Blog Highlights: Walmart, NVIDIA, Procter & Gamble, Phillips 66 and AstraZeneca

2017-11-21 zacks
Chicago, IL – November 21, 2017 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Walmart (WMT - Free Report) , NVIDIA (NVDA - Free Report) , Procter & Gamble (PG - Free Report) , Phillips 66 (PSX - Free Report) and AstraZeneca (AZN - Free Report) . (115-0)

Top Research Reports on Walmart, NVIDIA and Procter & Gamble

2017-11-20 zacks
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Walmart (WMT), NVIDIA (NVDA) and Procter & Gamble (PG). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today. (142-0)

Roche Rocks On With More Good News

2017-11-20 seekingalpha
One reported positive though not fully complete outcomes data on Tecentriq, with global filings in first-line metastataic lung cancer expected based on the data. (54-0)

Merck & Co. - Blue Chip Pharmaceutical At 52-Week Lows

2017-11-20 seekingalpha
Merck & Co. (MRK) is a global healthcare company that provides prescription medicine, vaccines, biologic therapies, and animal health products. Merck operates in four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. Most recent trailing twelve month revenues were just over $40B. Earnings per share over the last 12 months were $1.85. Free cash flow totaled $8.5B and equated to $3. (42-0)

Your Daily Pharma Scoop: Geron's Fate, Celldex Commences Mid-Stage Study, Novartis's Tasigna

2017-11-20 seekingalpha
This abridged “Daily Scoop” is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. (141-1)

Foreign Stock Roundup: JD.com Beats Estimates, Petrobras & Infineon Miss

2017-11-20 zacks
Political uncertainty in the United Kingdom and commodity prices weighed on Europe’s stocks over last week. Asia’s energy stocks also suffered losses even as economic data from China came in below expectations. Meanwhile, Brazil’s investors remained worried about President Temer’s ability to push through pension reforms even as dismal results from a state run oil major dragged stocks lower. (103-0)

Two Experimental Roche Drugs Succeed in Key Patient Studies - Bloomberg

2017-11-20 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world. (107-0)

Earnings Visibility Make AstraZeneca (AZN) a Buy

2017-11-17 investorplace
AstraZeneca Plc (NYSE:AZN) is a $83.3 billion in market value constituent of the Pharmaceuticals GICS industry group where the ranking for AZN by Portfolio Grader places it 37 among the 132 companies in this industry group, giving it an above-average position. AZN is ranked in the top half of the sector with a ranking of 267 among the 782 companies in the sector and number 1,662 in the 5000 company Portfolio Grader company universe. (35-0)

Texas Lawsuit Claims This Drugmaker Pushed Antipsychotic to Kids - Bloomberg

2017-11-17 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world. (35-0)

Why It’s Time to Put Pfizer Inc. Stock on Your Watchlist

2017-11-17 investorplace
Ever since its cholesterol-fighting drug Lipitor lost the crux of its patent protection back in 2011, Pfizer Inc. (NYSE:PFE) investors have approached PFE stock with caution. And, perhaps for good reason. Though the PFE stock price has almost doubled since generic versions of Lipitor were introduced (bear in mind Pfizer shares suffered plenty before the drug fell off the patent cliff), revenue only began to grow again last year. (123-0)

Cancer Space Update: Label Expansion for Three Major Drugs

2017-11-17 zacks
With a busy earnings season almost coming to an end after an impressive run, we are again focused on latest cancer updates happening every week. The week gone by saw three cancer drugs receiving FDA approval for new indications – Roche Holding AG’s (RHHBY - Free Report) Gazyva, Pfizer Inc.’s (PFE - Free Report) Sutent and AstraZeneca PLC’s (AZN - Free Report) Faslodex. However, an interesting product in development is a cancer vaccine that Moderna Therapeutics and Merck (MRK - Free Report) are working on. (396-1)

CUSIP: 046353108